argenx SE reported $744.12M in Operating Expenses for its fiscal quarter ending in June of 2025.


Operating Expenses Change Date
AstraZeneca USD 10.95B 1.04B Jun/2025
Galapagos EUR 122.32M 111.37M Jun/2025
Genmab DKK 565M 38M Jun/2025
GlaxoSmithKline GBP 5.96B 663M Jun/2025
GRIFOLS EUR 1.54B 24.64M Jun/2025
Hikma Pharmaceutical USD 1.31B 63M Dec/2024
Qiagen NV USD 397.57M 39.27M Jun/2025
UCB EUR 2.36B 108M Dec/2024